Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | +10.07% | +10.07% | +95.36% |
04-17 | RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk | MT |
04-10 | Nuvation Bio Closes Acquisition of AnHeart Therapeutics | MT |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 210.5 | 1,851 | 419.3 | 330.6 | 703.9 | - | - |
Enterprise Value (EV) 1 | 210.5 | 1,851 | 419.3 | 330.6 | 703.9 | 703.9 | 703.9 |
P/E ratio | -50.9 x | -19.3 x | -4 x | -4.31 x | -7.58 x | -5.33 x | -5.36 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 853 x | 36.5 x |
EV / Revenue | - | - | - | - | - | 853 x | 36.5 x |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 17,988 | 217,788 | 218,393 | 218,944 | 262,636 | - | - |
Reference price 2 | 11.70 | 8.500 | 1.920 | 1.510 | 2.680 | 2.680 | 2.680 |
Announcement Date | 11/03/21 | 28/02/22 | 15/03/23 | 29/02/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 0.8252 | 19.29 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -32.1 | -43.55 | -93.32 | -119.7 | -99.82 | -125.4 | -195.8 | -189.1 |
Operating Margin | - | - | - | - | - | - | -23,722.23% | -980.43% |
Earnings before Tax (EBT) 1 | - | -41.66 | -86.85 | -104.2 | -75.8 | -100.7 | -162.5 | -163.6 |
Net income 1 | - | -64.28 | -86.85 | -104.2 | -75.8 | -100.7 | -162.5 | -163.6 |
Net margin | - | - | - | - | - | - | -19,695.46% | -848.17% |
EPS 2 | -0.1600 | -0.2300 | -0.4400 | -0.4800 | -0.3500 | -0.3533 | -0.5025 | -0.5000 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 12/11/20 | 11/03/21 | 28/02/22 | 15/03/23 | 29/02/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -22.79 | -29.61 | -28.19 | -37.87 | -29.34 | -24.34 | -26.52 | -26.13 | -26.34 | -20.83 | -27.53 | -28.83 | -33.37 | -35.67 | -51.1 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -21.98 | -25.13 | -21.29 | -34.86 | -27.2 | -20.84 | -21.73 | -20.64 | -19.65 | -13.79 | -21.23 | -22.63 | -27.44 | -29.42 | -44 |
Net income 1 | -21.98 | -25.13 | -21.29 | -34.86 | -27.2 | -20.84 | -21.73 | -20.64 | -19.65 | -13.79 | -21.23 | -22.63 | -27.44 | -29.42 | -44 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1100 | -0.1200 | -0.1000 | -0.1600 | -0.1200 | -0.1000 | -0.1000 | -0.0900 | -0.0900 | -0.0600 | -0.0950 | -0.0783 | -0.0883 | -0.0950 | -0.1100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 10/11/21 | 28/02/22 | 09/05/22 | 04/08/22 | 03/11/22 | 15/03/23 | 04/05/23 | 03/08/23 | 02/11/23 | 29/02/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | 0.15 | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 11/03/21 | 28/02/22 | 15/03/23 | 29/02/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.36% | 704M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- NUVB Stock
- Financials Nuvation Bio Inc.